Betahistine intranasal - Otifex Therapeutics

Drug Profile

Betahistine intranasal - Otifex Therapeutics

Alternative Names: AM-125; Betahistine dihydrochloride nasal spray; Intranasal Betahistine

Latest Information Update: 09 Feb 2017

Price : $50

At a glance

  • Originator University of Melbourne
  • Developer Otifex Therapeutics
  • Class Pyridines; Small molecules
  • Mechanism of Action Histamine H1 receptor agonists; Histamine H3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Otitis

Most Recent Events

  • 03 Feb 2017 Auris Medical Holding acquires intranasal betahistine from Otifex Therapeutics
  • 03 Feb 2017 Auris Medical plans a phase I trial for Meniere's disease and vestibular vertigo in undisclosed country
  • 22 Apr 2015 Otifex Therapeutics initiates enrolment in a phase Ib trial for Otitis (In volunteers) in Australia (ACTRN12615000657527)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top